Header Logo

Connection

Michael Silverberg to Acquired Immunodeficiency Syndrome

This is a "connection" page, showing publications Michael Silverberg has written about Acquired Immunodeficiency Syndrome.
  1. Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus. Clin Infect Dis. 2021 06 01; 72(11):1900-1909.
    View in: PubMed
    Score: 0.737
  2. Immunodeficiency, AIDS-related pneumonia, and risk of lung cancer among HIV-infected individuals. AIDS. 2017 04 24; 31(7):989-993.
    View in: PubMed
    Score: 0.554
  3. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS. 2012 Nov 13; 26(17):2223-31.
    View in: PubMed
    Score: 0.407
  4. Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care. J Gen Intern Med. 2009 Sep; 24(9):1065-72.
    View in: PubMed
    Score: 0.323
  5. AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol. 2007 Sep; 19(5):446-51.
    View in: PubMed
    Score: 0.284
  6. Fraction of cases of acquired immunodeficiency syndrome prevented by the interactions of identified restriction gene variants. Am J Epidemiol. 2004 Feb 01; 159(3):232-41.
    View in: PubMed
    Score: 0.222
  7. Hepatitis B care cascade among people with HIV/HBV coinfection in the North American AIDS Cohort Collaboration on Research and Design, 2012-2016. PLoS One. 2023; 18(9):e0290889.
    View in: PubMed
    Score: 0.215
  8. Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States. JAMA Netw Open. 2022 06 01; 5(6):e2215934.
    View in: PubMed
    Score: 0.197
  9. Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004-18: a cohort study. Lancet HIV. 2022 03; 9 Suppl 1:S2.
    View in: PubMed
    Score: 0.194
  10. Do contemporary antiretrovirals increase the risk of end-stage liver disease? Signals from patients starting therapy in the North American AIDS Cohort Collaboration on Research and Design. Pharmacoepidemiol Drug Saf. 2022 02; 31(2):214-224.
    View in: PubMed
    Score: 0.190
  11. Association between U.S. state AIDS Drug Assistance Program (ADAP) features and HIV antiretroviral therapy initiation, 2001-2009. PLoS One. 2013; 8(11):e78952.
    View in: PubMed
    Score: 0.109
  12. Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell Lymphoma. Clin Cancer Res. 2012 Sep 01; 18(17):4702-12.
    View in: PubMed
    Score: 0.099
  13. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008 Apr 23; 22(7):841-8.
    View in: PubMed
    Score: 0.074
  14. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007 Sep 12; 21(14):1957-63.
    View in: PubMed
    Score: 0.071
  15. Effectiveness of highly-active antiretroviral therapy by race/ethnicity. AIDS. 2006 Jul 13; 20(11):1531-8.
    View in: PubMed
    Score: 0.066

© 2024 Kaiser Permanente